Persistent weight loss with a non-invasive novel medical device to change eating behaviour in obese individuals with high-risk cardiovascular risk profile

被引:4
|
作者
von Seck, Peter
Sander, F. Martin [1 ]
Lanzendorf, Leon [2 ]
von Seck, Sabine [3 ]
Schmidt-Lucke, Andre [4 ]
Zielonka, Mirja [5 ]
Schmidt-Lucke, Caroline [5 ,6 ]
机构
[1] Dent Clin, Frankfurt, Germany
[2] Tech Univ Berlin, Dept Hlth Care Management, Berlin, Germany
[3] MSD SHARP & DOHME GMBH, Berlin, Germany
[4] Hygiea Hosp, Dept Internal Med, Berlin, Germany
[5] Charite, Berlin, Germany
[6] Medicoacad Consultings, Berlin, Germany
来源
PLOS ONE | 2017年 / 12卷 / 04期
关键词
DIETARY RESTRAINT; DISINHIBITION; PREVENTION; OVERWEIGHT;
D O I
10.1371/journal.pone.0174528
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In evidence-based weight-loss programs weight regain is common after an initial weight reduction. Eating slowly significantly lowers meal energy intake and hunger ratings. Despite this knowledge, obese individuals do not implement this behaviour. We, thus tested the hypothesis of changing eating behaviour with an intra-oral medical device leading to constant weight reduction in overweight and obesity. Six obese patients (6 men, age 56 +/- 14, BMI 29 +/- 2 kg / m(2)) with increased CVRF profile were included in this prospective study. All patients had been treated for obesity during the last 10 years in a single centre and had at least 3 frustrate evidence-based diets. Patients received a novel non-invasive intra-oral medical device to slow eating time. Further advice included not to count calories, to avoid any other form of diet, to take their time with their meals, and to eat whatever they liked. This device was used only during meals for the first 4 to 8 weeks for a total of 88 [20 - 160] hours. Follow-up period was 23 [15 - 38] months. During this period, patients lost 11% [5 - 20%] (p< 0.001) of their initial weight. At 12 months, all patients had lost > 5%, and 67% (4/6) achieved a > 10% bodyweight loss. In the course of the study, altered eating patterns were observed. There were no complications with the medical device. Of note, all patients continued to lose weight after the initial intervention period (p< 0.001) and none of them had weight regain. With this medical device, overweight and obese patients with a history of previously frustrating attempts to lose weight achieved a significant and sustained weight loss over two years. These results warrant the ongoing prospective randomised controlled trial to prove concept and mechanism of action.
引用
收藏
页数:13
相关论文
共 20 条
  • [1] Effect of weight loss with orlistat on cardiovascular disease risk prediction in high-risk obese adults
    Rissanen, A
    Rossner, S
    Chen, KW
    [J]. OBESITY RESEARCH, 2001, 9 : 191S - 191S
  • [2] Changes in individual cardiovascular disease risk factors produced by weight loss and orlistat in a high-risk obese population
    Rössner, S
    Rissanen, A
    Chen, KW
    [J]. OBESITY RESEARCH, 2001, 9 : 189S - 189S
  • [3] A novel non-invasive model to predict high-risk varices in cirrhotic patients
    Ng, Kelvin K. C.
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (03) : 530 - 532
  • [4] Quantitative and qualitative Analysis to assess a Change in the Eating Behavior and Mechanism of Action of a non-invasive novel Medical Products for Weight Loss for Overweight and Obesity
    Huettemann, Pia
    Nowak, Aleksandra
    Koenigsmann, Jessica
    von Seck, Peter
    Schmidt-Lucke, Andre
    Schmidt-Lucke, Caroline
    [J]. INTERNIST, 2018, 59 : S12 - S12
  • [5] Cardiac CT in asymptomatic diabetes mellitus: role of non-invasive atherosclerosis imaging in high-risk asymptomatic individuals
    Cademartiri, Filippo
    Maffei, Erica
    Nistri, Stefano
    Leipsic, Jonathon
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2015, 16 (10) : 1060 - 1061
  • [6] DISPARITY IN CARDIOVASCULAR RISK STRATIFICATION BETWEEN A NOVEL NON-INVASIVE ARTERIAL STIFFNESS METHOD AND THREE CONVENTIONAL RISK SCORES IN A HIGH RISK POPULATION
    Dutton, D.
    Fullerton, J.
    Gunarathne, A.
    Dimitri, W.
    Banerjee, P.
    Siyabalapitiya, S.
    Singer, D. R. J.
    [J]. HEART, 2010, 96 : A69 - A70
  • [7] Persistent Weight Reduction in Overweight and Obesity through an innovative non-invasive Medical Product and Influencing the individual obesity-associated Risk
    Nowak, Aleksandra
    Huettemann, Pia
    Koenigsmann, Jessica
    von Seck, Peter
    Schmidt-Lucke, Andre
    Schmidt-Lucke, Caroline
    [J]. INTERNIST, 2018, 59 : S16 - S16
  • [8] Novel, Non-Invasive, Swallable Device for Weight Loss in Overweight and Light Obese Patients. Results of the European Obalon Study Group Early Experience
    Genco, A.
    Giardiello, C.
    Del Papa, M.
    Francois, E.
    Longheval, G.
    Martin, P.
    Fehlert, A.
    Horbach, T.
    Merkle, R.
    TurroArau, R.
    Breviere, G. Lopez-Nava
    Redler, A.
    [J]. OBESITY SURGERY, 2013, 23 (08) : 1183 - 1184
  • [9] Effect of a Web-Based Behavior Change Program on Weight Loss and Cardiovascular Risk Factors in Overweight and Obese Adults at High Risk of Developing Cardiovascular Disease: Randomized Controlled Trial
    Watson, Sinead
    Woodside, Jayne V.
    Ware, Lisa J.
    Hunter, Steven J.
    McGrath, Alanna
    Cardwell, Christopher R.
    Appleton, Katherine M.
    Young, Ian S.
    McKinley, Michelle C.
    [J]. JOURNAL OF MEDICAL INTERNET RESEARCH, 2015, 17 (07)
  • [10] Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial
    Andersson, Charlotte
    Weeke, Peter
    Fosbol, Emil Loldrup
    Brendorp, Bente
    Kober, Lars
    Coutinho, Walmir
    Sharma, Arya M.
    Van Gaal, Luc
    Finer, Nick
    James, W. Philip T.
    Caterson, Ian D.
    Rode, Richard A.
    Torp-Pedersen, Christian
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (08): : 1109 - 1115